| Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer S Awasthi, A Berglund, J Abraham-Miranda, RJ Rounbehler, K Kensler, ... Clinical Cancer Research 27 (1), 320-329, 2021 | 64 | 2021 |
| Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer A El-Kenawi, W Dominguez-Viqueira, M Liu, S Awasthi, ... Cancer research 81 (21), 5477-5490, 2021 | 60 | 2021 |
| Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and … Z Yuan, D Fernandez, J Dhillon, J Abraham-Miranda, S Awasthi, Y Kim, ... Prostate cancer and prostatic diseases 24 (1), 140-149, 2021 | 23 | 2021 |
| Furosemide: Triethanolamine salt as a strategy to improve the biopharmaceutical properties and photostability of the drug J Abraham Miranda, C Garnero, AK Chattah, Y Santiago de Oliveira, ... Crystal Growth & Design 19 (4), 2060-2068, 2019 | 18 | 2019 |
| Investigating a soluble pharmaceutical salt: albendazole hydrochloride A Bongioanni, MS Bueno, J Abraham-Miranda, AK Chattah, AP Ayala, ... Crystal Growth & Design 19 (8), 4538-4545, 2019 | 17 | 2019 |
| Characterization of systems with amino-acids and oligosaccharides as modifiers of biopharmaceutical properties of furosemide JA Miranda, C Garnero, A Zoppi, V Sterren, AP Ayala, MR Longhi Journal of Pharmaceutical and Biomedical Analysis 149, 143-150, 2018 | 16 | 2018 |
| Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer K Yamoah, S Awasthi, BA Mahal, SG Zhao, GD Grass, A Berglund, ... European urology 81 (4), 325-330, 2022 | 12 | 2022 |
| Immunologic disparities in prostate cancer between American men of African and European descent J Abraham-Miranda, S Awasthi, K Yamoah Critical reviews in oncology/hematology 164, 103426, 2021 | 5 | 2021 |
| Enhanced dissolution profiles of glibenclamide with amino acids using a cogrinding method VB Sterren, A Zoppi, J Abraham-Miranda, MR Longhi Materials Today Communications 26, 102126, 2021 | 5 | 2021 |
| Structural and dynamic characterization of solid furosemide polymorphs by NQR and NMR methods A Wolfenson, SC Perez, MJ Zuriaga, C Garnero, JA Miranda, M Longhi, ... Chemical Physics Letters 641, 163-168, 2015 | 5 | 2015 |
| CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production J Abraham-Miranda, M Menges, R Atkins, M Mattie, J Kanska, J Turner, ... Frontiers in Immunology 13, 1007042, 2022 | 4 | 2022 |
| Evaluating ternary systems with oligosaccharides as a strategy to improve the biopharmaceutical properties of furosemide J Abraham-Miranda, C Garnero, A Zoppi, AK Chattah, VB Sterren, ... Materials Science and Engineering: C 111, 110793, 2020 | 2 | 2020 |
| A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel DK Hansen, LC Peres, JA Miranda, K Reid, G De Avila, D Huggar, ... Blood 142, 1004, 2023 | 1 | 2023 |
| Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis … CLL Freeman, JA Miranda, M Menges, J Noble, H Liu, S Corallo, ... Blood 142, 1931, 2023 | 1 | 2023 |
| Clinical Impact of Neoantigen Burden and HLA Loss in Aggressive B-Cell Lymphomas Treated with CD19 CAR T-Cell B Ziccheddu, MD Jain, M Chojnacka, M Durante, JA Miranda, M Menges, ... Blood 142, 4362, 2023 | | 2023 |
| Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience LC Peres, P Patwardhan, D Huggar, G De Avila, LB Oswald, ... Blood 142, 5081, 2023 | | 2023 |
| CD19 Intron Retention Is Mechanism of CAR-T Treatment Resistance in Non-Hodgkin Lymphoma J Noble, FL Locke, C Savid-Frontera, MD Jain, JG Turner, JA Miranda, ... Blood 142, 3506, 2023 | | 2023 |
| CAR-T Phenotype and Efficacy Is Impaired By Lymphoma-Associated CD39+ T Cells MD Jain, X Yu, R Atkins, JG Turner, J Noble, M Menges, K Reid, S Corallo, ... Blood 142, 3500, 2023 | | 2023 |
| 193 CAR-T manufactured from frozen PBMC yield efficient function with delayed in vitro expansion J Abraham-Miranda, M Menges, R Atkins, M Mattie, J Kanska, J Turner, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Immunogenomic landscape of grade group 5 prostate cancer predicts risk of lethal outcomes and may inform treatment response K Yamoah, S Awasthi, B Mahal, SG Zhao, J Abraham-Miranda, TA Gerke, ... Cancer Research 80 (16_Supplement), 3520-3520, 2020 | | 2020 |
Shivanshu AwasthiH Lee Moffitt Cancer Center在 moffitt.org 的电子邮件经过验证
